Cataplexy - Clinical aspects, pathophysiology and management strategy

Nature Reviews Neurology

Volumn 10, Issue 7, 2014, Pages 386-395

  Dauvilliers, Yves ^a   Siegel, Jerry M ^b   Lopez, Regis ^a   Torontali, Zoltan A ^c   Peever, John H ^c  

^a INSERM U1061   (France)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 HYDROXYBUTYRIC ACID; ALEMTUZUMAB; AMPHETAMINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; CITALOPRAM; CLOMIPRAMINE; CORTICOSTEROID; DULOXETINE; FLUOXETINE; IMMUNOGLOBULIN; MAZINDOL; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; OREXIN; OXYBATE SODIUM; PROTRIPTYLINE; REBOXETINE; SELEGILINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AMYGDALOID NUCLEUS; BRAIN STEM; CATAPLEXY; DISEASE COURSE; DISEASE MANAGEMENT; DOG; DRUG MECHANISM; EMOTION; EVENING DOSAGE; HUMAN; MOUSE; MUSCLE WEAKNESS; NONHUMAN; PARALYSIS; PATHOPHYSIOLOGY; PLASMAPHERESIS; PREFRONTAL CORTEX; PRIORITY JOURNAL; QUALITY OF LIFE; REM SLEEP; REVIEW; SKELETAL MUSCLE; UNSPECIFIED SIDE EFFECT; WAKEFULNESS; ANIMAL; BRAIN; ELECTROENCEPHALOGRAPHY; MOOD DISORDERS; NERVE DEGENERATION; OCULAR MOTILITY DISORDERS; PATHOLOGY;

ANIMALS; BRAIN; CATAPLEXY; ELECTROENCEPHALOGRAPHY; HUMANS; MOOD DISORDERS; MUSCLE WEAKNESS; NERVE DEGENERATION; OCULAR MOTILITY DISORDERS;

EID: 84904044256     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2014.97     Document Type: Review

References (114)

1. American Academy of Sleep Medicine. The international classification of sleep disorders, revised. Diagnostic and coding manual. European Society of Sleep Technology [online], http://www.esst.org/adds/ICSD.pdf (2001).
2. Dauvilliers, Y., Arnulf, I. & Mignot, E. Narcolepsy with cataplexy. Lancet 369, 499-511 (2007).
3. Overeem, S., Mignot, E., van Dijk, J. G. & Lammers, G. J. Narcolepsy: Clinical features, new pathophysiologic insights, and future perspectives. J. Clin. Neurophysiol. 18, 78-105 (2001).
4. Dauvilliers, Y., Billiard, M. & Montplaisir, J. Clinical aspects and pathophysiology of narcolepsy. Clin. Neurophysiol. 114, 2000-2017 (2003).
5. Dauvilliers, Y. et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 57, 2029-2033 (2001).
6. Daniels, E., King, M. A., Smith, I. E. & Shneerson, J. M. Health-related quality of life in narcolepsy. J. Sleep Res. 10, 75-81 (2001).
7. Beusterien, K. M. et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 22, 757-765 (1999).
8. Burgess, C. R. & Peever, J. H. A noradrenergic mechanism functions to couple motor behavior with arousal state. Curr. Biol. 23, 1719-1725 (2013).
9. Siegel, J. M. Functional implications of sleep development. PLoS Biol. 3, e178 (2005).
10. Chemelli, R. M. et al. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. Cell 98, 437-451 (1999).
11. Hara, J. et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30, 345-354 (2001).
12. Lin, L. et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98, 365-376 (1999).
13. Willie, J. T. et al. Distinct narcolepsy syndromes in Orexin receptor 2 and Orexin null mice: Molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron 38, 715-730 (2003).
14. Peyron, C. et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 6, 991-997 (2000).
15. Thannickal, T. C. et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27, 469-474 (2000).
16. Mignot, E. et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol. 59, 1553-1562 (2002).
17. Mignot, E. et al. Complex HLA-DR and-DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am. J. Hum. Genet. 68, 686-699 (2001).
18. Faraco, J. et al. ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLoS Genet. 9, e1003270 (2013).
19. Hallmayer, J. et al. Narcolepsy is strongly associated with the T cell receptor alpha locus. Nat. Genet. 41, 708-711 (2009).
20. Kornum, B. R. et al. Common variants in P2RY11 are associated with narcolepsy. Nat. Genet. 43, 66-71.
21. Dauvilliers, Y. et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain 136, 2486-2496 (2013).
22. Hor, H. et al. Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat. Genet. 42, 786-789.
23. Partinen, M. et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE 7, e33723 (2012).
24. Luca, G. et al. Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: A European Narcolepsy Network study. J. Sleep Res. 22, 482-495 (2013).
25. Overeem, S. et al. The clinical features of cataplexy: A questionnaire study in narcolepsy patients with and without hypocretin 1 deficiency. Sleep Med. 12, 12-18.
26. Nishino, S. & Mignot, E. Narcolepsy and cataplexy. Handb. Clin. Neurol. 99, 783-814 (2011).
27. Sturzenegger, C. & Bassetti, C. L. The clinical spectrum of narcolepsy with cataplexy: A reappraisal. J. Sleep Res. 13, 395-406 (2004).
28. Mayer, G. The neurophysiology of cataplexy [German]. Nervenarzt 76, 1464-1469 (2005).
29. Vetrugno, R. et al. Behavioural and neurophysiological correlates of human cataplexy: A video-polygraphic study. Clin. Neurophysiol. 121, 153-162 (2010).
30. Billiard, M., Besset, A. & Cadilhac, J. in Sleep/Wake Disorders: Natural History, Epidemiology and Long-Term Evolution (eds C. Guilleminault & E. Lugaresi) 171-185 (Raven Press, 1983).
31. Mattarozzi, K. et al. Clinical, behavioural and polysomnographic correlates of cataplexy in patients with narcolepsy/cataplexy. Sleep Med. 9, 425-433 (2008).
32. Plazzi, G. et al. Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. Brain 134, 3480-3492 (2011).
33. Pizza, F. et al. Clinical and polysomnographic course of childhood narcolepsy with cataplexy. Brain 136, 3787-3795 (2013).
34. American Academy of Sleep Medicine. The International Classification of Sleep Disorders-Third Edition (ICSD-3). AASM Resource Library [online], (2014).
35. Andlauer, O. et al. Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep 35, 1247-1255F (2012).
36. Thannickal, T. C., Nienhuis, R. & Siegel, J. M. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep 32, 993-998 (2009).
37. Han, F. et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann. Neurol. 70, 410-417 (2011).
38. De la Herran-Arita, A. K. et al. CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy. Sci. Transl. Med. 5, 216ra176 (2013).
39. Aran, A. et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 32, 979-983 (2009).
40. Cvetkovic-Lopes, V. et al. Elevated Tribbles homolog 2 specific antibody levels in narcolepsy patients. J. Clin. Invest. 120, 713-719 (2010).
41. Burgess, C. R., Oishi, Y., Mochizuki, T., Peever, J. H. & Scammell, T. E. Amygdala lesions reduce cataplexy in orexin knock-out mice. J. Neurosci. 33, 9734-9742 (2013).
42. Plazzi, G. et al. Narcolepsy with cataplexy associated with holoprosencephaly misdiagnosed as epileptic drop attacks. Mov. Disord. 25, 780-782.
43. Overeem, S., Lammers, G. J. & van Dijk, J. G. Weak with laughter. Lancet 354, 838 (1999).
44. Overeem, S., Reijntjes, R., Huyser, W., Lammers, G. J. & van Dijk, J. G. Corticospinal excitability during laughter: Implications for cataplexy and the comparison with REM sleep atonia. J. Sleep Res. 13, 257-264 (2004).
45. Siegel, J. M. & Boehmer, L. N. Narcolepsy and the hypocretin system-where motion meets emotion. Nat. Clin. Pract. Neurol. 2, 548-556 (2006).
46. Mensen, A., Poryazova, R., Schwartz, S. & Khatami, R. Humor as a reward mechanism: Event-related potentials in the healthy and diseased brain. PLoS ONE 9, e85978 (2014).
47. Reiss, A. L. et al. Anomalous hypothalamic responses to humor in cataplexy. PLoS ONE 3, e2225 (2008).
48. Ponz, A. et al. Abnormal activity in reward brain circuits in human narcolepsy with cataplexy. Ann. Neurol. 67, 190-200 (2010).
49. Hong, S. B., Tae, W. S. & Joo, E. Y. Cerebral perfusion changes during cataplexy in narcolepsy patients. Neurology 66, 1747-1749 (2006).
50. Dauvilliers, Y. et al. A brain PET study in patients with narcolepsy-cataplexy. J. Neurol. Neurosurg. Psychiatry 81, 344-348 (2010).
51. Blouin, A. M. et al. Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction. Nat. Commun. 4, 1547 (2013).
52. Gulyani, S., Wu, M. F., Nienhuis, R., John, J. & Siegel, J. M. Cataplexy-related neurons in the amygdala of the narcoleptic dog. Neuroscience 112, 355-365 (2002).
53. Siegel, J. M. Narcolepsy: A key role for hypocretins (orexins). Cell 98, 409-412 (1999).
54. Vassalli, A. et al. Electroencephalogram paroxysmal theta characterizes cataplexy in mice and children. Brain 136, 1592-1608 (2013).
55. Siegel, J. M. et al. Neuronal activity in narcolepsy: Identification of cataplexy-related cells in the medial medulla. Science 252, 1315-1318 (1991).
56. Espana, R. A., McCormack, S. L., Mochizuki, T. & Scammell, T. E. Running promotes wakefulness and increases cataplexy in orexin knockout mice. Sleep 30, 1417-1425 (2007).
57. Clark, E. L., Baumann, C. R., Cano, G., Scammell, T. E. & Mochizuki, T. Feeding-elicited cataplexy in orexin knockout mice. Neuroscience 161, 970-977 (2009).
58. Peever, J. Control of motoneuron function and muscle tone during REM sleep, REM sleep behavior disorder and cataplexy/narcolepsy. Arch. Ital. Biol. 149, 454-466 (2011).
59. Luppi, P. H. et al. The neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behavior disorder. Sleep Med. Rev. 15, 153-163 (2011).
60. Ristanovic, R. K., Liang, H., Hornfeldt, C. S. & Lai, C. Exacerbation of cataplexy following gradual withdrawal of antidepressants: Manifestation of probable protracted rebound cataplexy. Sleep Med. 10, 416-421 (2009).
61. Kodama, T., Lai, Y. Y. & Siegel, J. M. Changes in inhibitory amino acid release linked to pontine-induced atonia: An in vivo microdialysis study. J. Neurosci. 23, 1548-1554 (2003).
62. Lai, Y. Y. & Siegel, J. M. Medullary regions mediating atonia. J. Neurosci. 8, 4790-4796 (1988).
63. Mileykovskiy, B. Y., Kiyashchenko, L. I., Kodama, T., Lai, Y. Y. & Siegel, J. M. Activation of pontine and medullary motor inhibitory regions reduces discharge in neurons located in the locus coeruleus and the anatomical equivalent of the midbrain locomotor region. J. Neurosci. 20, 8551-8558 (2000).
64. Brooks, P. L. & Peever, J. H. Identification of the transmitter and receptor mechanisms responsible for REM sleep paralysis. J. Neurosci. 32, 9785-9795 (2012).
65. Wu, M. F. et al. Locus coeruleus neurons: Cessation of activity during cataplexy. Neuroscience 91, 1389-1399 (1999).
66. John, J., Wu, M. F., Boehmer, L. N. & Siegel, J. M. Cataplexy-Active neurons in the hypothalamus: Implications for the role of histamine in sleep and waking behavior. Neuron 42, 619-634 (2004).
67. Hasegawa, E., Yanagisawa, M., Sakurai, T. & Mieda, M. Orexin neurons suppress narcolepsy via 2 distinct efferent pathways. J. Clin. Invest. 124, 604-616 (2014).
68. Wu, M. F. et al. Activity of dorsal raphe cells across the sleep-waking cycle and during cataplexy in narcoleptic dogs. J. Physiol. 554, 202-215 (2004).
69. Peyron, C. et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18, 9996-10015 (1998).
70. Peever, J. H., Lai, Y. Y. & Siegel, J. M. Excitatory effects of hypocretin 1 (orexin A) in the trigeminal motor nucleus are reversed by NMDA antagonism. J. Neurophysiol. 89, 2591-2600 (2003).
71. Lee, M. G., Hassani, O. K. & Jones, B. E. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J. Neurosci. 25, 6716-6720 (2005).
72. Mileykovskiy, B. Y., Kiyashchenko, L. I. & Siegel, J. M. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron 46, 787-798 (2005).
73. Siegel, J. M. et al. Activity of medial mesopontine units during cataplexy and sleep-waking states in the narcoleptic dog. J. Neurosci. 12, 1640-1646 (1992).
74. Siegel, J. M. et al. Neuronal degeneration in canine narcolepsy. J. Neurosci. 19, 248-257 (1999).
75. Wu, M. F., Nienhuis, R., Maidment, N., Lam, H. A. & Siegel, J. M. Role of the hypocretin (orexin) receptor 2 (Hcrt r2) in the regulation of hypocretin level and cataplexy. J. Neurosci. 31, 6305-6310 (2011).
76. Grimaldi, D., Silvani, A., Benarroch, E. E. & Cortelli, P. Orexin/hypocretin system and autonomic control: New insights and clinical correlations. Neurology 82, 271-278 (2014).
77. John, J. et al. Greatly increased numbers of histamine cells in human narcolepsy with cataplexy. Ann. Neurol. 74, 786-793 (2013).
78. Valko, P. O. et al. Increase of histaminergic tuberomammillary neurons in narcolepsy. Ann. Neurol. 74, 794-804 (2013).
79. LeDoux, J. The amygdala. Curr. Biol. 17, R868-R874 (2007).
80. Schwartz, S. et al. Abnormal activity in hypothalamus and amygdala during humour processing in human narcolepsy with cataplexy. Brain 131, 514-522 (2008).
81. Lu, J., Sherman, D., Devor, M. & Saper, C. B. A putative flip-flop switch for control of REM sleep. Nature 441, 589-594 (2006).
82. Kaur, S. et al. Hypocretin 2 saporin lesions of the ventrolateral periaquaductal gray (vlPAG) increase REM sleep in hypocretin knockout mice. PLoS ONE 4, e6346 (2009).
83. Covington, H. E. 3rd et al. Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex. J. Neurosci. 30, 16082-16090 (2010).
84. Nishino, S. & Mignot, E. Pharmacological aspects of human and canine narcolepsy. Prog. Neurobiol. 52, 27-78 (1997).
85. Burgess, C. R., Tse, G., Gillis, L. & Peever, J. H. Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy. Sleep 33, 1295-1304 (2010).
86. Reid, M. S. et al. Neuropharmacological characterization of basal forebrain cholinergic stimulated cataplexy in narcoleptic canines. Exp. Neurol. 151, 89-104 (1998).
87. Billiard, M. et al. EFNS guidelines on management of narcolepsy. Eur. J. Neurol. 13, 1035-1048 (2006).
88. Parkes, J. D. & Schachter, M. Clomipramine and clonazepam in cataplexy. Lancet 2, 1085-1086 (1979).
89. Aran, A. et al. Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: A retrospective study of 51 children. Sleep 33, 1457-1464.
90. Ratkiewicz, M. & Splaingard, M. Treatment of cataplexy in a three year old using venlafaxine. J. Clin. Sleep Med. 9, 1341-1342 (2013).
91. Larrosa, O., de la Llave, Y., Bario, S., Granizo, J. J. & Garcia-Borreguero, D. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: A pilot study. Sleep 24, 282-285 (2001).
92. Niederhofer, H. Atomoxetine also effective in patients suffering from narcolepsy? Sleep 28, 1189 (2005).
93. Pistis, M. et al. γ-hydroxybutyric acid (GHB) and the mesoaccumbens reward circuit: Evidence for GABAB receptor-mediated effects. Neuroscience 131, 465-474 (2005).
94. [No authors listed]. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 25, 42-49 (2002).
95. Alshaikh, M. K. et al. Sodium oxybate for narcolepsy with cataplexy: Systematic review and meta-Analysis. J. Clin. Sleep Med. 8, 451-458 (2012).
96. Wang, Y. G., Swick, T. J., Carter, L. P., Thorpy, M. J. & Benowitz, N. L. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): Abuse, misuse, dependence, and diversion. J. Clin. Sleep Med. 5, 365-371 (2009).
97. Wang, Y. G., Swick, T. J., Carter, L. P., Thorpy, M. J. & Benowitz, N. L. Sodium oxybate: Updates and correction to previously published safety data. J. Clin. Sleep Med. 7, 415-416 (2011).
98. Kastin, A. J. & Kerstrom, V. Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. J. Pharmacol. Exp. Ther. 289, 219-223 (1999).
99. John, J., Wu, M. F. & Siegel, J. M. Systemic administration of hypocretin 1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res. Online 3, 23-28 (2000).
100. Deadwyler, S. A., Porrino, L., Siegel, J. M. & Hampson, R. E. Systemic and nasal delivery of orexin A (hypocretin 1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J. Neurosci. 27, 14239-14247 (2007).
101. Baier, P. C. et al. Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal orexin A (hypocretin 1). Brain 131, 2734-2741 (2008).
102. Baier, P. C. et al. Effects of intranasal hypocretin 1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med. 12, 941-946 (2011).
103. Weinhold, S. L. et al. The effect of intranasal orexin A (hypocretin 1) on sleep, wakefulness and attention in narcolepsy with cataplexy. Behav. Brain Res. 262, 8-13 (2014).
104. Kantor, S. et al. Orexin gene therapy restores the timing and maintenance of wakefulness in narcoleptic mice. Sleep 36, 1129-1138 (2013).
105. Arias-Carrion, O. et al. Transplantation of hypocretin neurons into the pontine reticular formation: Preliminary results. Sleep 27, 1465-1470 (2004).
106. Dauvilliers, Y. et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: A double-blind, randomised trial. Lancet Neurol. 12, 1068-1075 (2013).
107. Lin, J. S. et al. An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: Studies in orexin-/-mice and patients. Neurobiol. Dis. 30, 74-83 (2008).
108. Dauvilliers, Y., Carlander, B., Rivier, F., Touchon, J. & Tafti, M. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann. Neurol. 56, 905-908 (2004).
109. Lecendreux, M., Maret, S., Bassetti, C., Mouren, M. C. & Tafti, M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10 year old boy. J. Sleep Res. 12, 347-348 (2003).
110. Plazzi, G. et al. Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J. Neurol. 255, 1549-1554 (2008).
111. Chen, W., Black, J., Call, P. & Mignot, E. Late-onset narcolepsy presenting as rapidly progressing muscle weakness: Response to plasmapheresis. Ann. Neurol. 58, 489-490 (2005).
112. Donjacour, C. E. & Lammers, G. J. A remarkable effect of alemtuzumab in a patient suffering from narcolepsy with cataplexy. J. Sleep Res. 21, 479-480 (2012).
113. Dauvilliers, Y., Abril, B., Mas, E., Michel, F. & Tafti, M. Normalization of hypocretin 1 in narcolepsy after intravenous immunoglobulin treatment. Neurology 73, 1333-1334 (2009).
114. Dauvilliers, Y. et al. Cerebrospinal fluid and serum cytokine profiles in narcolepsy with cataplexy: A case-control study. Brain Behav. Immun. 37, 260-266 (2014).